HU197200B - Process for preparing jelly relieving and regenerating respiration - Google Patents

Abstract

Breathing difficulties and unpleasant symptoms as head and/or ear ache, dry mouth, diminuation of sense of smell are caused by physiological deterioration of the mucous membrane of the nose and also by dry rhinitis (rhinitis sicca). Such compliants, which reached epidemic proportions can be cured or allocated by treatment and maintenance doses of a nasal gel.

Description

Many factors, or a combination of these, can cause adverse changes in the condition of the nasal passages or dry them. Decreased air humidity, various physical, chemical, infectious, upper respiratory tract infections, intoxications, drug side effects, vitamin deficiencies, anatomical changes as well as internal factors can cause nasal dryness (9, 17, 19, 20, 21, 22, 23, 28,).

Changes in the physiological state of the nasal mucosa and inflammation of the nose are associated with unpleasant symptoms (difficulty or inhibition of nasal breathing, headache, uncertain earache, discharge of mucus, glassy mucus from the throat, dehydration of the mucous membrane, dry mouth, smell, smell of the mouth). cases of rhinitis, spot bleeding, etc.). If the process persists for a prolonged period of time, you will experience dry, unproductive coughing, sneezing, difficulty breathing, and difficulty in breaking down secretions after going to bed or immediately after getting up. This condition predisposes to certain diseases, such as infections (17).

Although there is no accurate assessment in the literature of the incidence of the aforementioned adverse effects on the nasal mucosa or dry nasal mucosa (rhinitis sicca) in the general population or in certain populations, the condition or set of needles is very common among patients seeking a referral.

One of the applicants of the present invention, in their survey of their own practice, found that this condition was present in 43% of the patients requesting a specialist.

All these support the public health significance of the unfavorable changes in the physiological state of the nasal mucosa and dry rhinitis (rhinitis sicca).

The composition of the gel of the invention is as follows:

Rp.

Phase I

(Vehicle) CarbopolMO 1.0 Triethanolamin 1.2 Oleum helianthi 5.0 Aqua destillata 70.0 Sol. Conservans 2.0 (Ph. Hg. VI.)

Ung. hydrophyl. grow. 15.0 g (Ph. Hg. VI.)

II. phase (active ingredient)

Inj. Vitamin E amp.N ° III. (3x30 mg) (0.09 g) Inj. Vitamin A amp.N ° III. (300,000 IU) (0.3 g) _ Inj. Panthenol amp.N ° II. (2x0.5 g) (1.0 g) Caps. Vitamin F Ν ^θ X. (2.7 g in 6.0 g oil)

III. phase (essential oils)

Aetheroleum thymi 0.5 g

Aetheroleum eucalipti 0.5 g

Aetheroleum menthae pip. 0.5 g

Technological description:

Carbopolaio is well mixed with 30 g of water at 50 ° C, swollen briefly (5 minutes), and the remaining 40 g of cooled (5 ° C) water is added to Triethanolamine and this mixture is stirred continuously , saponifying the swollen Carbopol. To the resulting stable gel, add 15 g of Unguentum hydrophylicum nonionicum and 5 g of sunflower oil, slowly and with constant stirring, then a mixture of the active ingredients and finally a mixture of essential oils. It is important to keep the temperature (50 ° C).

The resulting Vitamin Breath Opener Gel may be dosed at any desired dosage. It is advisable to fill the composition inside enamelled metal tubes to avoid drying.

The novelty of the invention is essentially that no patent ointment, gel, or other agent for the repair of the nasal mucosa is found, either in the literature or in the patents available, to provide regeneration of the nasal mucosa. For application; they have the effect of promoting nasal ointments or mucous membranes and peeling epithelium that have accumulated on the nasal mucosa, cleansing the mucous membranes (eg, Unguentum Nasale, Azulenol ointment), or in the case of back injuries (eg, after surgery, trauma), They are symptomatic treatment, the latter cannot be used in case of dry inflammation of the nasal mucosa (rhinitis sicca) as their application to the body is not completely indifferent.

The nasal mucosa regenerating effect is believed to be due to the beneficial synergistic effect of the substances present in the composition in the amounts described herein.

In addition to the above, the claimed agent has some other advantages over those used hitherto for nasal administration, which will be described below with reference to the present invention.

The advanced nature of the present invention is that dry rhinitis (rhinitis sicca) is known to affect large masses according to the literature. Since the claimed invention contributes to the causal elimination of rhinitis sicca by restoring mucosal integrity, it satisfies an unmet need. Of particular note is the high demand for the solution, the public health significance of rhinitis sicca, and the fact that the invention can prevent the development of circulatory processes that often occur on the soil of rhinitis sicca and may have more severe consequences for the body. The advanced nature of the invention is also underlined by its role in secondary prevention. 20

The present invention is not qualitatively comparable to the prior art agents used nasally because they are unsuitable for regeneration of the nasal mucosa, but merely represents a symptomatic treatment, but it should be noted that the majority of the therapeutic agents used contain which, in addition to the acceptable risk in therapy, would not allow the application of the mass sizes required for rhinitis sicca, since the application of these substances to the body is not completely inert (silver nitrate, boric acid, ephedrine).

The agent disclosed in the present invention does not contain substances which would cause damage to the body either at the indicated dosage or at significantly higher doses than recommended. Thus, the invention can be safely applied. Its advanced nature and utility is further enhanced by the fact that, in addition to regenerating mucous membranes, it also significantly improves respiration.

It is also to be noted in connection with the progressive nature of the invention that extraordinary situations may occur in which the significance of the invention may increase (eg defense aspects). It also has a clear occupational health significance.

To date, no agents have been disclosed to regenerate mucosal lesions characteristic of rhinitis sicca.

The gel of the present invention was examined and found that of the 78 patients with a non-physiological condition or 55 of the rhinitis sicca treated with the above-mentioned composition of the gels, 20 were patients with nasal mucosa, patients showed a significant improvement and only a modest improvement was observed in 11 patients.

Patients were required to receive jelly treatment according to the seasonal nature of the condition, primarily in the period October to May, with intensive maintenance for 10 days to two weeks (application of jelly 3-4 times daily). dosing should be applied to the nasal mucosa only once daily, preferably at bedtime.

In the literature, a similar formulation has been found as a nasal ointment or jelly for the treatment of the above-mentioned condition and of dry rhinitis (rhinitis sicca).

Literature:

1. Atukorala, S. et al .: Br.J.Cancer. 40927-31. (1979)

2. Basa, T.K. et al .: Int.J., Vitam.Nutr.Res.44.14-18 (1974).

3. Cammer, P. et al .: Am.Rev.Reps.Dis.112.807. (1975)

4. MsCormich.D.L. et al .: J.N.C.I. 66. 559-64 (1981).

5. Erődi, A .: Ear Nose and Throat Medicine, 18,241. (1972)

6. Farrington, K. et al .: Br.Med.J. 282.1999-2002. (1982)

7. Gyeney, L .: Ear Nose and Throat Medicine, 22.182. (1976)

8. Hamdy, R.C. et al., Chain 11.1103-04. (1982)

9. Imrei, L .: Ear Nose and Throat Medicine, 19.11. (1973)

10. Jakab, T., Szilágyi, J.: Ear Nose and Throat Medicine, 22.188. (1976)

11. Jasper, A .: Ear Nose and Throat Medicine, 10.45 (1964)

12. Kark.J.D, et al., Br.Med.J.284.152-4. (1982)

13. Kark, J, D, et al .: Br.Med.J.N.C.I.66.7-16. (1981)

14. Maxwell, J.D. et al .: Obstetr.Gynecol.888987-91. (1981)

15. Patty, J. et al .: Chain ΙΙ.876. (1982)

16. Róbert, M., Romom, MD .: Laryngoscope, ll. 1802-1804. (1973)

17. Proetz, A.W .: Arch.Otolaryng. 19 607. (1937)

18. Sporn, M.B. et al .: Fed.Proc.35.1332-38. (1976)

19. Straub.M.J .: J.Path.Bact.45.75-78. (1937)

20. Straub.M.J .: J.Path.Bact.50.31-36. (1940)

21. Straub, M., Mulder, J.: J.Path.Bact.60.429-34.

(1948) ^X

22. Szabó, E .: Orv. Weekly, 108.16. (1967)

23. Szabó, E .: Ear-nose-throat medicine, 27,231-236. (1981)

24. Untill Silt., Jakab, T .: Ear Nose and Throat Medicine, 21.179. (1975)

25. Szövérffy, L., Spellenberg, S., Váli, F: Ear Nose and Throat Medicine, 22.51. (1976)

26. h'ald, N. et al .: Chain II. 813-5. (1980)

27. Wagner, A, F, Falkers, K .: Vitaminé and Coenzymes.Interscience Publishers (A Division of John Wiley and Sons), New York, London, Sydney (1964) - pp.281-330.

28. Wilhelm.D.L .: J.Path.Bact.67.361-65. (1954)

29. Willett, W.C. et al .: New England J.Med. 310-430-34. (1984)

Claims (3)

PATENT CLAIMS 1.) A process for the preparation of a respiratory and regeneration gel comprising: I.Carbopol940 as carrier in 0.5-2%, triethanolamine in 1-3%, sunflower oil in 2-10%, distilled water in 30-80%. , sol. conservanst (Ph.Hg.VI.) 1-4%, Ung. Hydrophyl. nonion. in 10-20% and as active ingredient II. Vitamin E in 0.05-0.1%, Vitamin A in 0.1-0.5%, Panthenol in 0.5-2%, Vitamin F in 5-10% and Essential Oils in the following percentages; III. Aetheroleum thymit 0.1-1%, eucalyptus oil 0.1-1% and peppermint oil 0.1-1% are mixed into a pharmaceutical composition. 2. A process according to claim 1, characterized in that the Carbopolwo is mixed with a portion of the water and swollen for a short time, then mixed with the triethanolamine in the remaining water, followed by the addition of an aqueous portion of the preservative solution. Unguentum hydrophylicum nonionicum, sunflower oil, mixture II and finally III were added to 10 stable gels, and the mixture was homogenized at 40-60 ° C. 3. The adversary process of claim 1 or 2, wherein the final homogenization is preferably carried out at 50 ° C. without drawing